[1]刘成,杨宗国,陆云飞,等.消黄方对大鼠胆汁淤积性肝纤维化的干预作用*[J].西部中医药,2012,25(11):14-17.
　LIU Cheng,YANG Zong-guo,LU Yun-fei,et al.Therapeutic Effects of XiaoHuangFang on Cholestatic Liver Fibrosis in Rats[J].Western Journal of Traditional Chinese Medicine,2012,25(11):14-17.
点击复制

消黄方对大鼠胆汁淤积性肝纤维化的干预作用*
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
25
期数:
2012年11期
页码:
14-17
栏目:
出版日期:
2012-11-15

文章信息/Info

Title:
Therapeutic Effects of XiaoHuangFang on Cholestatic Liver Fibrosis in Rats
文章编号:
1004-6852(2012)11-0014-04
作者:
刘成1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2，杨宗国1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2，陆云飞1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2，陈晓蓉1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2△
1 上海市(复旦大学附属)公共卫生临床中心，上海 201508； 2 国家中医药管理局中医药防治传染病重点研究室(临床基地)
Author(s):
LIU Cheng1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2, YANG Zong-guo1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2, LU Yun-fei1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2, CHEN Xiao-rong1，2' target="_blank" rel="external">2' target="_blank" rel="external">2' target="_blank" rel="external">2△
1 Shanghai Public Health Clinical Center (A ffiliated to Fudan University), Shanghai 201508, China; 2 Key Laboratory of TCM for Infectious Disease in State A dministration of Traditional Chinese Medicine
关键词:
肝纤维化; 消黄方; 胆管结扎
Keywords:
liver fibrosis;  XiaoHuangFang;  bile duct ligation
分类号:
R575.22
文献标志码:
A
摘要:
目的：观测消黄方对胆管结扎大鼠肝功能及组织病理学的干预作用。方法：Wistar大鼠30只，随机分为假手术组和胆管结扎组(BDL)。BDL大鼠在2周末随机分为消黄方组和模型组，第3周开始消黄方组每天灌胃给药，假手术组和BDL组灌胃等量生理盐水，共3周。5周末处死全部大鼠，获取血清和肝组织样本。结果：与假手术组相比，模型组血清谷草转氨酶(ALT)，谷丙转氨酶(AST)和碱性磷酸酶(ALP)活性及总胆红素(TBIL)含量显著上升(P＜0.05或0.01)，白蛋白(Alb)含量显著下降(P＜0.01);与模型组相比，消黄方显著降低ALP活性和TBIL含量，显著抑制 Alb含量的降低(P＜0.05或0.01)，降低肝组织Hyp含量(P＜0.05)，同时病理学显示消黄方组肝纤维化程度也显著减轻。结论：消黄方能显著抑制胆汁淤积性肝纤维化的形成。
Abstract:
Objective: To explore the intervention of XiaoHuangFang on liver function and histopathology of rats with bile duct ligation. Method: Thirty rats were randomized into sham operation group and bile duct ligation (BDL) group. Rats in BDL group were divided into XiaoHuangFang group and model group by the end of two weeks, XiaoHuangFang group began to receive intragastric administration from the third week, sham operation group and BDL group received lavage of same amounts of psychological saline for three weeks. All the rats were sacrificed by the end of fifth week to obtain the serum and liver tissue. Result: Compared with sham operation group, activities of ALT, AST and ALP of model group and contents of TBIL remarkably increased (P＜0.05 or 0.01), contents of Alb lowered notably (P＜0.01); compared with model group, XiaoHuangFang can lower the activity of ALP and the content of TBIL remarkably, inhibit the decrease of Alb contents(P＜0.05 or 0.01) and reduce the contents of Hyp in liver tissue (P＜0.05), meanwhile pathology of liver fibrosis in XiaoHuangFang group showed that it relieved. Conclusion: XiaoHuangFang can obviously inhibit the formation of cholestatic liver fibrosis.

参考文献/References:

［1］ 刘成，陈晓蓉，陆云飞，等.消黄方对急慢性黄疸治疗作用实验研究［J］.辽宁中医药大学学报，2011，13(11)：50-52. ［2］ Zhang Y，Hong JY，Rockwell CE，et al.Effect of bile duct ligation on bile acid composition in mouse serum and liver［J］.Liver Int，2012：32(1)：58-69. ［3］ Gall JA，Bhathal PS.A quantitative analysis of the liver following ligation of the common bile duct［J］.Liver，1990，10(2)：116-125. ［4］ Liu C，Tao Q，Sun M，et al.Kupffer cells are associated with apoptosis，inflammation and fibrotic effects in hepatic fibrosis in rats［J］.Lab Invest，2010，90 (12)：1805-1816. ［5］ Trebicka J，Hennenberg M，Odenthal M，et al.Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells［J］.J Hepatol，2010，53(4)：702-712. ［6］ 龙爱华，刘平，李风华，等.大鼠胆汁淤积性肝硬化的动态病理变化及其意义［J］.中西医结合肝病杂志，2006，16(2)：87-89. ［7］ 武荣芳，张俊平，曹银香，等.膈下逐瘀汤对实验性肝硬化大鼠血液流变学的影响［J］.河北中医,2008,30(8)：877-878. ［8］ 赵艳，张伯鹏，宋春霞，等.黄芪注射液联合腹水超滤浓缩回输术治疗肝硬化腹水的疗效观察［J］.河北中医，2009，31(5):743-744. ［9］ 刘平.“病 - 证 - 效”结合研究的思考与探索［J］.上海中医药大学学报，2007，21(1)：4-7. ［10］陆云飞，陈晓蓉，慕永平，等.消黄方联合西药治疗难治性黄疸 51 例临床观察［J］.上海中医药杂志，2010，44(5)：60-62. ［11］陈进凡，刘媛，柳渊洁，等.肠毒清口服液对全身炎症反应综合征大鼠体质量及进食量的影响［J］.西部中医药，2011，24(11):28-31. ［12］靳萱，高如宏，乔建荣.芳香类药物配伍应用治疗急性、亚急性湿疹六法［J］.西部中医药，2011，24(8):17-19. ［13］龙爱华，刘平，李风华，等.从不同功效方剂干预大鼠胆汁淤积性肝硬化的效用探讨取效方证病机［J］.中医药学报，2008，36(2)：9-12. ［14］刘成，刘平，陶庆，等.茵陈蒿汤干预二甲基亚硝胺大鼠肝硬化效应的方证病理学基础研究［J］.中国中西医结合杂志，2010，30(8)：845-850. ［15］Huang W，Zhang J，Moore DD.A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR［J］.J Clin Invest，2004，113(1)：137-143. ［16］Ma T，Huang C，Zong G，et al.Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis［J］.J Pharm Pharmacol，2011，63 (4)：587-593. ［17］ Chin YY，Liong SY，Ton SH，et al.Amelioration of glucose homeostasis by glycyrrhizic acid through gluconeogenesis rate-limiting enzymes［J］.Eur J Pharmacol，2012，667(1-3)：197-202.

相似文献/References:

[1]于立友,汪龙德△,张晶,等.化纤保肝方治疗气滞血瘀型肝纤维化的临床研究*[J].西部中医药,2013,26(10):84.
　YU Liyou,WANG Longde,ZHANG Jing,et al.Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(11):84.
[2]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2014,27(06):13.
　GUO Shouqiang.The Effects of Matrine on the Expressions of TGF-β1 of the Rats with Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2014,27(11):13.
[3]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(11):84.
[4]陈耀章,李根旺.冬虫夏草对心肝肾的保护作用研究[J].西部中医药,2016,29(04):127.
　CHEN Yaozhang,LI Genwang.Study on the Protective Effects of DongChong XiaCao to Heart, Liver and Kidney[J].Western Journal of Traditional Chinese Medicine,2016,29(11):127.
[5]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(11):149.
[6]段桂姣,王振常,吴珊珊.柔肝化纤颗粒对肝纤维化模型大鼠肝组织超氧化物歧化酶和丙二醛的影响[J].西部中医药,2022,35(04):30.[doi:10.12174/j.issn.2096-9600.2022.04.08]
　DUAN Guijiao,WANG Zhenchang,Wu Shanshan.Effects of Rougan Huaxian Granules on SOD and MDA in Liver Tissue of Rats with Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(11):30.[doi:10.12174/j.issn.2096-9600.2022.04.08]
[7]徐俊,戚璐,许杰,等.抗纤软肝颗粒对肝纤维化小鼠肠道黏膜通透性的影响[J].西部中医药,2022,35(07):27.[doi:10.12174/j.issn.2096-9600.2022.07.07]
　XU Jun,QI Lu,XU Jie,et al.Influence of Anti-fibrosis Liver-softening Granules on Intestinal Mucosal Permeability in Hepatic Fibrosis Mice[J].Western Journal of Traditional Chinese Medicine,2022,35(11):27.[doi:10.12174/j.issn.2096-9600.2022.07.07]
[8]李莎,焦战,陈青,等.瞬时弹性成像技术评价自拟中药治疗肝纤维化的临床疗效[J].西部中医药,2020,33(08):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
　LI Sha,JIAO Zhan,CHEN Qing,et al.Clinical Effects of Selfmade Herbs in Treating Liver Fibrosis Evaluated by Transient Elastography[J].Western Journal of Traditional Chinese Medicine,2020,33(11):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
[9]陈懿榕,阙任烨,刘进锴,等.柴胡皂苷d对大鼠肝星状细胞TGFβ-Smad信号通路mRNA表达的影响[J].西部中医药,2022,35(08):15.[doi:10.12174/j.issn.2096-9600.2022.08.04]
　CHEN Yirong,QUE Renye,LIU Jinkai,et al.Influence of Saikosaponins-d on the Expressions of TGFβ-Smad Signal Path mRNA in Rat Hepatic Stellate Cells[J].Western Journal of Traditional Chinese Medicine,2022,35(11):15.[doi:10.12174/j.issn.2096-9600.2022.08.04]
[10]郭召平,苏琴,黄天生.化痰助运通络方治疗痰瘀互结型非酒精性脂肪肝肝纤维化临床研究[J].西部中医药,2021,34(05):122.[doi:10.12174/j.issn.2096-9600.2021.05.31]
　GUO Zhaoping,SU Qin,HUANG Tiansheng.Clinical Study on Treating Non Alcoholic Fatty Liver Fibrosis of Phlegm and Blood Stasis Pattern by Resolving-phlegm Promoting-transportation Dredging-collateral Prescription[J].Western Journal of Traditional Chinese Medicine,2021,34(11):122.[doi:10.12174/j.issn.2096-9600.2021.05.31]

备注/Memo

备注/Memo:
收稿日期：2012-05-07 * 基金项目：国家“十一五”科技重大专项子课题(2009ZX10005-019)，上海市科学技术委员会项目(编号 25382；10411963000)，上海市卫生局项目(编号 2011Y020)，中央高校基本科研业务费专项资金资助(编号 10F115) 作者简介：刘成(1982—)，男，博士学位，助理研究员。研究方向：传染病、肝病的中医药防治。 △通讯作者：陈晓蓉(1964—)，女，主任医师。研究方向：传染病、肝病的中医药防治及基础研究。
更新日期/Last Update: 2012-11-15